JOURNAL OF PSYCHOACTIVE DRUGS, published by Routledge Journals, Taylor & Francis Ltd, stands as a leading resource in the fields of psychology and medicine, focusing on the intersection of psychoactive substances and their impact on human behavior. With an ISSN of 0279-1072 and E-ISSN 2159-9777, this esteemed journal has been a pivotal platform for rigorous research since its inception in 1967, contributing to the understanding of drug use, its societal implications, and therapeutic potentials. It currently holds a Q2 ranking in both the miscellaneous categories of Medicine and Psychology for 2023, reflecting its significant standing within academic circles. Moreover, its Scopus rankings place it at the 49th percentile in General Psychology and 101st in Medicine, underscoring its relevance in contemporary research. Although it is not available via Open Access, the journal maintains a commitment to advancing knowledge through its annual publications until 2024. JOURNAL OF PSYCHOACTIVE DRUGS is essential for researchers, professionals, and students seeking to explore the complexities of psychoactive substances and their effects in various contexts.

DRUG AND ALCOHOL REVIEW, published by Wiley, is a leading journal dedicated to advancing the scholarship in the fields of drug and alcohol research. Since its inception in 1989, this esteemed publication has provided a critical platform for the dissemination of innovative research findings, reviews, and theoretical papers, addressing pressing issues in substance use and addiction. With an impact factor that places it in the Q1 category in both Health (social science) and Medicine (miscellaneous), it ranks #78 out of 371 in the Scopus index for Health and #115 out of 398 in Medicine, reflecting its significant influence and high citation rates among scholars. The journal is committed to fostering a multidisciplinary approach, integrating perspectives from psychology, sociology, public health, and medicine, to inform policy and practice. Accessible to researchers and practitioners alike, *DRUG AND ALCOHOL REVIEW* serves as an essential resource for anyone invested in understanding and addressing the complexities of drug and alcohol use in society.

Substance Abuse: Research and Treatment is a premier open-access journal published by SAGE Publications Ltd, focusing on the multifaceted aspects of substance use and its impact on mental health. Since its establishment in 2008, this journal has been dedicated to disseminating innovative research findings, case studies, and reviews that enhance understanding and treatment of substance-related disorders. With an impact factor that reflects its standing in the field, currently ranked in the Q2 category of Psychiatry and Mental Health, Substance Abuse: Research and Treatment strives to foster interdisciplinary dialogue among researchers, practitioners, and students. By making its content freely accessible, the journal encourages widespread engagement and application of evidence-based practices to mitigate substance abuse issues. The journal’s diverse global perspectives make it a vital resource for anyone invested in advancing knowledge and improving treatment outcomes in this critical area of public health.

Welcome to the Journal of Addiction Medicine, a premier academic resource devoted to the field of addiction studies, published by LIPPINCOTT WILLIAMS & WILKINS. Since its inception in 2007, this esteemed journal has become a leader in disseminating groundbreaking research, with impressive rankings in the Q1 quartile across key disciplines such as Medicine (Miscellaneous), Pharmacology (Medical), and Psychiatry and Mental Health, reflecting its significance in the scholarly community. With an ISSN of 1932-0620 and an E-ISSN of 1935-3227, it caters to a diverse audience of researchers, clinicians, and students seeking to expand their understanding of addiction medicine. The journal's articles are primarily published in a non-open access format, ensuring high-quality research is accessible through institutional subscriptions. With a Scopus ranking that positions it within the top tiers of several relevant categories, the Journal of Addiction Medicine is essential for anyone committed to advancing knowledge in the field and addressing the complexities surrounding addiction.

Welcome to the Harm Reduction Journal, a premier academic platform published by BMC, dedicated to advancing the field of harm reduction since its inception in 2004. With an impressive track record as an Open Access publication, this journal addresses critical topics within the broad scope of medicine, psychiatry, and public health, making it indispensable for researchers, healthcare professionals, and students alike. As of 2023, it proudly holds a Q1 ranking in prestigious categories including Medicine (Miscellaneous), Psychiatry and Mental Health, and Public Health, Environmental and Occupational Health, reflecting its high impact and significance in the academic community. The journal is notable for its comprehensive discussions on innovative harm reduction strategies, public policy considerations, and evidence-based practice, fostering collaboration and knowledge exchange. With a global reach and commitment to enhancing health outcomes, the Harm Reduction Journal serves as a vital resource in the ever-evolving landscape of public health and addiction research.

Advances in Dual Diagnosis, published by EMERALD GROUP PUBLISHING LTD, serves as a vital resource for professionals and researchers in the fields of psychiatry and mental health. With an ISSN of 1757-0972 and E-ISSN 2042-8324, this journal has been at the forefront of dual diagnosis research since its inception in 2008, aiming to bridge the gap in knowledge and practice regarding the co-occurrence of mental health disorders and substance use issues. Rated in the Q4 category for Psychiatry and Mental Health, it ranks 31st out of 45 in Nursing and Psychiatric Mental Health and 408th out of 567 in Medicine and Psychiatry, providing a unique platform for showcasing emerging research, innovative treatment strategies, and case studies that enhance understanding of complex patient needs. While the journal is not openly accessible, its contributions are crucial for driving forward the academic discourse and practical applications surrounding dual diagnosis. As we look to the future through 2024 and beyond, the Advances in Dual Diagnosis journal continues to strive for excellence in disseminating knowledge that benefits practitioners and scholars alike.

CONTEMPORARY DRUG PROBLEMS is a distinguished academic journal published by SAGE PUBLICATIONS INC, focusing on critical issues within the realms of drug policy, health advocacy, and law. With a legacy dating back to its inception in 1973 and a noticeable convergence in subsequent years, the journal serves as a vital forum for researchers, practitioners, and policymakers engaged in understanding the multifaceted challenges related to drug use and its societal impacts. Holding an impressive Q2 ranking in both Health Policy and Health (social science), and a Q1 distinction in Law, the journal positions itself as an essential resource for advancing knowledge and fostering dialogue in these essential fields. Although it operates under traditional access models, its wide-ranging insights make it indispensable for those who aim to contribute meaningfully to the discourse surrounding contemporary drug issues. With its robust Scopus rankings, including a significant 89th percentile in Social Sciences Law, CONTEMPORARY DRUG PROBLEMS remains a pivotal source for scholars and professionals alike, striving to address and mitigate the complexities of drug-related problems on both a legal and social front.

DRUGS-EDUCATION PREVENTION AND POLICY is a premier scholarly journal published by Taylor & Francis Ltd, focusing on the critical intersection of drug education, prevention strategies, and policy formulation. Established in 1994 and continuing through its converged years into 2024, this journal holds significant relevance within the health and social sciences fields, with commendable standings reflected in its 2023 category quartile rankings of Q2 in both Health (Social Science) and Medicine (Miscellaneous). With an impact ranking that places it in the 73rd and 67th percentiles respectively, it serves as an influential platform for researchers, professionals, and students to disseminate innovative research, case studies, and policy analyses. Those interested in the complexities of drug-related issues are encouraged to explore the insights provided by this journal, contributing to the ongoing discourse in effective prevention and education practices in the context of drug use and its social implications. Although access to articles is not open, the wealth of knowledge presented is invaluable for academia and policy formulation alike.

ADDICTIVE BEHAVIORS is a prestigious journal published by PERGAMON-ELSEVIER SCIENCE LTD, specializing in the critical examination and exploration of addiction-related issues across diverse fields including Clinical Psychology, Psychiatry and Mental Health, and Toxicology. With a robust history dating back to 1975 and convergence extending to 2024, the journal is esteemed for its rigorous peer-reviewed research that contributes significantly to understanding addiction phenomena. Ranked in the Q1 category for its focus areas, it stands out within the academic community, evidenced by its impressive Scopus rankings—25th in Clinical Psychology and 14th in Toxicology—placing it in the top tier of its disciplines. This journal offers valuable insights into addiction behaviors, treatment methodologies, and public health implications, making it an essential resource for researchers, practitioners, and students seeking to advance their knowledge and impact the field. Although not Open Access, it provides vital access options for institutions and individuals invested in addiction studies.

Substance Abuse Treatment, Prevention, and Policy is a premier open access journal published by BMC, dedicated to advancing the understanding and improvement of substance abuse treatment and prevention strategies. Since its inception in 2006, this journal has established itself as a significant resource in the fields of Health Policy and Psychiatry and Mental Health, proudly maintaining a strong reputation reflected in its 2023 Scopus rankings, which place it in the top quartiles of these categories. With an impactful focus on policy implications and evidence-based practices, the journal's comprehensive coverage supports the sharing of innovative research and perspectives aimed at mitigating substance abuse challenges worldwide. Open access since its launch, it ensures that vital research is readily available to researchers, practitioners, and students alike, facilitating collaboration and discourse in this critical area of public health. Its commitment to high-quality research is underscored by its rankings within the 78th percentile for Health Policy and 66th percentile for Psychiatry and Mental Health, highlighting its influence and relevance in addressing pressing issues in substance misuse.